Lifshitz Law PLLC Announces Investigations of Fortrea Holdings, Inc. (NASDAQ:FTRE), Vestis Corporation (NYSE:VSTS), PepGen Inc. (NASDAQ:PEPG), and Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

June 19, 2025 at 14:59 PM EDT

NEW YORK, NY / ACCESS Newswire / June 19, 2025 / Fortrea Holdings, Inc. (NASDASQ:FTRE)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. Fortrea was formerly the clinical development and commercialization services business of Labcorp Holdings Inc., a life sciences and healthcare company. In June 2023, Labcorp spun off Fortrea as a standalone, publicly traded company. In connection with the Spin-Off, Labcorp and Fortrea entered into several transition services agreements (the "TSAs"), pursuant to which Fortrea pays Labcorp to provide certain transitional services for a set period, including information technology applications, network and security support and hosting, as well as finance, human resources, marketing, and other administrative support.

The Company allegedly made false and misleading statements and/or failed to disclose that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you are an FTRE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Vestis Corporation (NYSE: VSTS)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. The Company provided investors with material information concerning Vestis' expected growth for the fiscal year 2025. The Company's statements included, among other things, confidence in their forecasting ability and, in turn, in their ability to execute strategic initiatives to improve customer experience and retention while enacting annual price increases.

Allegedly, the Company provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis' ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers.

If you are a VSTS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

PepGen Inc. (NASDAQ: PEPG)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. PepGen had been evaluating PGN-EDO51 as a treatment for Duchenne muscular dystrophy in two Phase 2 clinical trials - the CONNECT1-EDO51 ("CONNECT1") and CONNECT2-EDO51 ("CONNECT2") studies. At all relevant times, the Company touted PGN-EDO51's clinical, regulatory, and commercial prospects, including PGN-EDO51's ability to produce the dystrophin protein and the design, prospects, and results of the CONNECT1 and CONNECT2 studies.

The Company allegedly made false and/or misleading statements and/or failed to disclose that: (1) PGN-EDO51 was less effective and safe than the Company had led investors to believe; (2) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. FDA approval; (3) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading.

If you are a PEPG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. Allegedly, the Company provided investors with material information concerning Rocket's Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease. The Company's statements included, among other things, confidence in the drug's safety and efficacy, as well as the clinical trial's detailed protocol and Rocket's purported ability to meet the trial's endpoints as per the Company's ascribed timeline.

The Company allegedly provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RPA501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders.

If you are a RCKT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

ATTORNEY ADVERTISING.© 2025 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: jlifshitz@lifshitzlaw.com

SOURCE: Lifshitz Law PLLC

View the original press release on ACCESS Newswire

About Us

Laser Focus World Membership

Magazine Subscription

Newsletter Subscription

The Daily Beam

Product Watch

Bio & Life Sciences Product Watch

Laser Processing Product Watch

Get Published!

Photonics Hot List

Following the Photons: A Photonics Podcast

Social Media

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

Lifshitz Law PLLC Announces Investigations of Fortrea Holdings, Inc. (NASDAQ:FTRE), Vestis Corporation (NYSE:VSTS), PepGen Inc. (NASDAQ:PEPG), and Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

More News